In silico study of porphyrin-anthraquinone hybrids as CDK2 inhibitor
Sign Up to like & getrecommendations! Published in 2017 at "Computational biology and chemistry"
DOI: 10.1016/j.compbiolchem.2016.12.005
Abstract: Cyclin-Dependent Kinases (CDKs) are known to play crucial roles in controlling cell cycle progression of eukaryotic cell and inhibition of their activity has long been considered as potential strategy in anti-cancer drug research. In the… read more here.
Keywords: silico study; cdk2 inhibitor; porphyrin anthraquinone; anthraquinone hybrids ... See more keywords
Accelerated Discovery of Macrocyclic CDK2 Inhibitor QR-6401 by Generative Models and Structure-Based Drug Design.
Sign Up to like & getrecommendations! Published in 2023 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.2c00515
Abstract: Selective CDK2 inhibitors have the potential to provide effective therapeutics for CDK2-dependent cancers and for combating drug resistance due to high cyclin E1 (CCNE1) expression intrinsically or CCNE1 amplification induced by treatment of CDK4/6 inhibitors.… read more here.
Keywords: cdk2 inhibitor; generative models; macrocyclic cdk2; drug ... See more keywords